Licensed for treating relapsing multiple sclerosis in Europe since 2017.
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Licensed for treating relapsing multiple sclerosis in Europe since 2017.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023